Tonix collaborated with the University of Maryland to develop TNX-1500 for the prevention of rejection in xenograft transplantation in animals. Revivicor will provide genetically modified porcine hearts for UMB’s preclinical studies
TNX-1500 showed activity in preventing allograft and xenograft organ rejection and was well tolerated in the previous preclinical studies in non-human primates. The result supported an IND application and human clinical studies
Additionally, the P-I study of TNX-1500 is expected to be initiated in Q2’23. TNX-1500 is an Fc-modified humanized mAb directed against CD40-ligand while Tonix highlighted results from 3 oral presentations at ATC 2022
Ref: Globenewswire | Image: Tonix
Related News:- Tonix Entered into a Sponsored Research Agreement with Boston Children’s Hospital to Study TNX-1500 for the Prevention of Graft-Versus-Host Disease in Animals
